Guideline
Members are eligible for GEP testing as follows:
I.
Advanced cancer; next generation sequencing (NGS), when performed with a diagnostic lab test that has received FDA approval or clearance (e.g., Foundation One CDx) Covered for Medicare members only when the following criteria are met: 1. Member has i. either recurrent, relapsed, refractory, metastatic, or advanced stages III or IV cancer; and ii. either not been previously tested using the same NGS test for the same primary diagnosis of cancer or repeat testing using the same NGS test only when a new primary cancer diagnosis is made by the treating physician; and iii. decided to seek further cancer treatment (e.g., therapeutic chemotherapy) 2. The diagnostic laboratory test using NGS must have: i. FDA approval or clearance as a companion in vitro diagnostic; and ii. an FDA approved or cleared indication for use in that patient's cancer; and iii. results provided to the treating physician for management of the patient using a report template to specify treatment options 
II.
Confirmation of consumer-based testing (including, but not limited to Health + Ancestry [23andMe] has not been shown to be of clinical value and remains experimental/investigational. Testing will be approved only for members who otherwise meet the clinical criteria in these policies
III.
Whole exome sequencing and whole genome sequencing are not considered medically necessary due to insufficient evidence of therapeutic value for all indications, including but not limited to: 1. Diagnosis in members with suspected genetic disorders 2. Population-based screening 3. Cancer testing to identify targeted therapies 4. Preimplantation genetic diagnosis and screening 5. Invasive prenatal (fetal) testing 6. Products of conception and pregnancy loss 7. Testing for chromosomal rearrangements
IV.
The following GEP tests are not considered medically necessary due to insufficient evidence of therapeutic value (list not all-inclusive; note exceptions): 
